Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Piaserico, S; Osto, E; Famoso, G; Zanetti, I; Gregori, D; Poretto, A; Iliceto, S; Peserico, A; Tona, F.
Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.
Atherosclerosis. 2016; 251:25-30 Doi: 10.1016/j.atherosclerosis.2016.05.036
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Osto Elena

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND AND AIMS: In patients with psoriasis, the chronic exposure to systemic inflammation can result in coronary microvascular dysfunction (CMD). In this self-controlled, prospective pilot study, we investigated whether a long-term treatment with TNF-α inhibitors effective against skin symptoms also improves coronary flow reserve in psoriasis patients (CFR). METHODS: We prospectively studied 37 consecutive psoriasis patients (31 male; age, 37.7 ± 8.5 years) without cardiovascular disease, before and after anti-TNF-α treatment. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. A CFR≤2.5 was considered a marker of CMD. Psoriasis was assessed by Psoriasis Area and Severity Index (PASI). High sensitive C-reactive protein (hs-CRP) and serum TNF-α were assessed. RESULTS: Overall, CFR increased from 2.2 ± 0.7 to 3.02 ± 0.8 (p < 0.0001) after TNF-α inhibitors therapy. In patients with CMD, CFR increased from 1.88 ± 0.3 to 2.74 ± 0.5 (p < 0.0001). In patients with normal CFR, CFR increased from 3.0 ± 0.5 to 3.7 ± 0.9 (p = 0.08). CFR improvement after TNF-α inhibitors treatment was correlated with hs-CRP and TNF-α reduction (p = 0.004 and p = 0.02, respectively), but not with change in PASI (p = 0.5). CONCLUSIONS: The present study demonstrates that TNF-α inhibitors treatment ameliorates CMD in patients with established psoriasis not responding to long-term conventional therapy. These findings suggest that a therapy specifically targeted against inflammation is able to positively affect coronary microvascular function.

Find related publications in this database (using NLM MeSH Indexing)

Adalimumab - therapeutic use

Adult - administration & dosage

C-Reactive Protein - analysis

Chronic Disease - administration & dosage

Coronary Angiography - administration & dosage

Coronary Circulation - drug effects

Coronary Vessels - physiopathology

Echocardiography, Doppler - administration & dosage

Etanercept - therapeutic use

Female - administration & dosage

Fractional Flow Reserve, Myocardial - administration & dosage

Humans - administration & dosage

Inflammation - blood, drug therapy

Infliximab - therapeutic use

Male - administration & dosage

Microcirculation - drug effects

Middle Aged - administration & dosage

Multivariate Analysis - administration & dosage

Pilot Projects - administration & dosage

Prospective Studies - administration & dosage

Psoriasis - blood, drug therapy, physiopathology

Tumor Necrosis Factor-alpha - antagonists & inhibitors, blood

Find related publications in this database (Keywords)

Coronary flow reserve

Coronary microcirculation

Inflammation

Risk factors

Psoriasis

© Med Uni Graz • Imprint